Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin + Lactulose in ACLF with Hepatic Encephalopathy
NCT02321371Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Oct 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in hepatic encephalopathy (HE) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Reduction of ammonia level to <70 mcg/dL at 72 hours. Started Oct 2014; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT02321371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321371.